Aim: To study the effect of human placenta-derived mesenchymal stem cells (hPMSCs) on cord blood CD8(+);T cell activation, cell cycle and secretion of IL-17, and to provide the theoretical basis for it application in the cell-based therapies.
Methods: hPMSCs were isolated from mature placenta by the method of digestion. Then hPMSCs were cultured, expanded in vitro, and were used in test after the third passage. CD8(+);T cells were sorted from cord blood with immunomagetic beads. FCM was used to analyze the expression of early activation phenotype, cell cycle of cord blood CD8(+);T cells and cytokine secretion.
Results: CD8(+);T cells stimulated by PHA in the presence of hPMSCs were arrested at G0/G1 phase. The expression of the early activation marker CD25 and CD69 of cord blood CD8(+);T cells was inhibited in the presence of hPMSCs. While, IL-17secretion of cord blood CD8(+);T cells stimulated by PMA was increased.
Conclusion: hPMSCs can suppress the activation of cord blood CD8(+);T cells by altering T cell cycle; up-regulate the level of IL-17 secreted by cord blood CD8(+);T cells.